title: CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CNF (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: results by demographic and clinical subgroups.
abstract: A multicenter phase III randomized study comparing the efficacies of two adjuvant polychemotherapeutic regimens in 145 patients with stage II node-positive breast cancer: the standard chemotherapy combination, CMF (cyclophosphamide, methotrexate, 5-fluorouracil), and an experimental protocol, CNF (cyclophosphamide, mitoxantrone [Novantrone], 5-fluorouracil) in which mitoxantrone replaced methotrexate. The finding of a significant advantage ( p= 0.04) in the disease-free survival for those receiving mitoxantrone (mean survival 4.4 years for CNF versus 2.7 years for CMF) led the authors to break the data down in subpopulations to determine exactly which groups of women responded more favorably to CNF than CMF. An advantage in disease-free survival was found, most notable in four subgroups: Sephardic women, women less than 45 years of age, premenopausal women, and women with 4 to 10 positive axillary lymph nodes. Although the small numbers of women in each of these subgroups rule out drawing definitive conclusions, the trend merits further study to confirm these observations.
authors.affiliation: Department of Oncology, Tel Aviv-Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors.forename: Ilan G
authors.initials: IG
authors.lastname: Ron
authors.forename: Nely
authors.initials: N
authors.lastname: Wigler
authors.forename: Riva
authors.initials: R
authors.lastname: Borovik
authors.forename: Tamar
authors.initials: T
authors.lastname: Peretz
authors.forename: Shulamith
authors.initials: S
authors.lastname: Rizel
authors.forename: Adi
authors.initials: A
authors.lastname: Shani
authors.forename: Joseph
authors.initials: J
authors.lastname: Brenner
authors.forename: Hannan
authors.initials: H
authors.lastname: Farbstein
authors.forename: Harold J
authors.initials: HJ
authors.lastname: Brenner
authors.forename: Samario
authors.initials: S
authors.lastname: Chaitchik
authors.forename: Raphael
authors.initials: R
authors.lastname: Catane
authors.forename: Moshe J
authors.initials: MJ
authors.lastname: Inbar
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000208:ethnology / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007585:Jews; D008207:Lymphatic Metastasis; D008727:Methotrexate / Q000008:administration & dosage; D008942:Mitoxantrone / Q000008:administration & dosage; D016019:Survival Analysis
chemical_list: D003520:Cyclophosphamide; D008942:Mitoxantrone; D005472:Fluorouracil; D008727:Methotrexate